Acadia Pharmaceuticals Inc

Overview

Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson’s disease psychosis. The company's pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, Major Depressive Disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has operational presence in Denmark, Switzerland and the UK. Acadia is headquartered in San Diego, California, the US.
Key Stats
Address
3611 Valley Centre Dr Ste 300, SAN DIEGO, California
Headquarters

United States of America

Contact

1 858 5582871

No of Employees

610

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ACAD [NASD]

Revenue (2020)

$442 m

30.4% (2020 vs 2019)
Net Income (2020)

$-282 m

-19.9% (2020 vs 2019)
Net Profit Margin

-64 %

8.1% (2020 vs 2019)
Market Cap *

$2,655 m

EPS *

$-1.8

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Acadia Pharmaceuticals IncPfizer Inc
Key Information
Headquarters United States of America United States of America
Headquarter City SAN DIEGO NEW YORK
Headquarter State/Province California New York
No. of Employees 610 78,500
Entity Type Public Public

Products & Services

Acadia focuses on discovery, development and marketing of small molecule drugs for the treatment of central nervous system disorders. The company's key pipeline products and brands include the following:

Products
  • Marketed:
  • Nuplazid
  • Pipeline Pimavanserin - Dementia-Related Psychosis
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Nuplazid
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Mark Schneyer Chief Business Officer; Senior Vice President - Business Development Senior Management 2020 - Mr. Mark Schneyer has been the Senior Vice President, Business Development and Chief Business Officer of the company since 2020....
Ponni Subbiah, M.D. Senior Vice President; Global Head - Medical Affairs; Chief Medical Officer Senior Management 2019 - Ms. Ponni Subbiah has been the Senior Vice President, the Global Head of Medical Affairs and the Chief Medical Officer...
Stephanie Fagan Chief Communications Officer; Senior Vice President - Corporate Affairs Senior Management 2019 - Mr. Stephanie Fagan been serving as the Senior Vice President, Corporate Affairs and Chief Communications Officer of the company from...
Amanda Morgan Chief Revenue and Customer Officer; Senior Vice President Senior Management 2019 - Ms. Amanda Morgan has been the Senior Vice President and the Chief Revenue and Customer Officer of the company since...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Contracts/Agreements In May, the company entered into an exclusive license agreement and research collaboration with Vanderbilt…
2020 Others In March 2020, the company and its partner, Neuren, received Rare Pediatric Disease (RPD) designation…
2020 Acquisitions/Mergers/Takeovers In August, the company acquired CerSci Therapeutics., a biotechnology company.
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


CerSci Therapeutics Inc

Address

Floor 33, 1601 Elm Street, Dallas
United States of America

Telephone

1 214 3066218

Website

www.cersci.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
24 Aug 2020 ACADIA Pharma Acquires CerSci Therapeutics Acquisition Acadia Pharmaceuticals Inc CerSci Therapeutics Inc
30 Jul 2020 Acadia Pharmaceuticals Inc Enters Phase III Clinical Trial Agreement with IQVIA Holdings Inc for pimavanserin tartrate (GDCT0378255) Contract Service Agreement Acadia Pharmaceuticals Inc; Acadia Pharmaceuticals Inc IQVIA Holdings Inc; IQVIA Holdings Inc
07 May 2020 ACADIA Pharma Enters into Licensing Agreement with Vanderbilt University Licensing Agreement Acadia Pharmaceuticals Inc Vanderbilt University
17 Sep 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
08 Jul 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
03 Jun 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

19

Active Jobs

0

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
Senior Director, Lifecycle Management Strategy Acadia Pharmaceuticals Inc United States
Director, New Product Planning Acadia Pharmaceuticals Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar